InvestorsObserver
×
News Home

Sotera Health Company Down 2.78% To $16.59 After Earnings Meet

Tuesday, February 27, 2024 10:43 AM | InvestorsObserver Analysts

Mentioned in this article

Sotera Health Company Down 2.78% To $16.59 After Earnings Meet

Sotera Health Co (SHC) missed earnings estimates for Q4 2023 this morning.

The consensus among analysts for Sotera Health Company was for an earnings per share (EPS) of $0.26. The firm failed to meet those projections, reporting an EPS of $0.26, a neutral surprise of $0. Profits rose 4% year-over-year after reporting an EPS of $0.25 in its year-ago quarter. The positive growth rate signals that the Healthcare company is performing decently amid recent economic conditions.

Analyst projections for Sotera Health Company revenue came in at a consensus of $302.2 million. Fourth-Quarter revenues surpassed estimates for $310.2 million by $8.1 million (3%). The company achieved 23% growth year-over-year compared to the firm's revenue of $251.6 million from the year-ago quarter. The lower earnings growth relative to revenue signals Sotera Health Company has not been able to improve its profit margin.

The stock is down 2.78% to $16.59 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Sotera Health Company a Bullish Sentiment Rank from InvestorsObserver.

Sotera Health Company has performed a little above average during the past few months. Before the report, Sotera Health Company received a Long-Term Technical Rank by InvestorsObserver of 55, putting it in the top half of stocks. The firm set a 52-week low on October 27, 2023 at $12.34 and set a 52-week high on July 19, 2023 at $19.4.

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are United States, Canada, Europe, and other regions.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App